David M. Tanen J.D. Net Worth

Mr. David M. Tanen J.D. biography

David M. Tanen J.D. is the Sec. & Director at Kronos Bio.

What is the salary of Mr D?

As the Sec. & Director of Kronos Bio, the total compensation of Mr D at Kronos Bio is $35,000. There are 4 executives at Kronos Bio getting paid more, with Jorge F. DiMartino M.D., Ph.D. having the highest compensation of $765,105.

How old is Mr D?

Mr D is 50, he's been the Sec. & Director of Kronos Bio since . There are 7 older and 3 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.

What's Mr D's mailing address?

David's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.

Insiders trading at Kronos Bio

Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger a Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.

What does Kronos Bio do?

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio executives and stock owners

Kronos Bio executives and other stock owners filed with the SEC include:

• Jorge F. DiMartino M.D., Ph.D.,
  Chief Medical Officer & Exec. VP of Clinical Devel.
• Dr. Norbert W. Bischofberger Ph.D.,
  Pres, CEO & Director
• Dr. Yasir B. Al-Wakeel BCh, BM, MA,
  CFO & Head of Corp. Devel.
• Dr. Norbert W. Bischofberger,
  Pres, CEO & Director
• David M. Tanen J.D.,
  Sec. & Director
• Joshua A. Kazam,
  Co-Founder & Director
• Marni Kottle,
  Sr. VP of Corp. Communications & Investor Relations
• Dr. Christopher Dinsmore Ph.D.,
  Chief Scientific Officer
• Barbara A. Kosacz J.D.,
  COO & Gen. Counsel
• Charles Lin Ph.D.,
  Sr. VP of Biology
• Dr. Pasit Phiasivongsa Ph.D.,
  Sr. VP of Pharmaceutical Devel.
• Stephanie Yao,
  Exec. Director of Investor Relations & Corp. Communications
• Dr. Christopher Dinsmore,
  Chief Scientific Officer
• Barbara A. Kosacz,
  COO & Gen. Counsel
• Dr. Yasir B. Al-Wakeel,
  CFO & Head of Corp. Devel.
• Norbert W Bischofberger,
  PRESIDENT & CEO
• Barbara Kosacz,
  COO & General Counsel
• Yasir B. Al Wakeel,
  Chief Financial Officer
• Christopher Dinsmore,
  Chief Scientific Officer
• Norbert W. & Inger A. Revoc...,
  10% owner
• Arie Belldegrun,
  
• Rebecka Belldegrun,
  Director
• Jakob Loven,
  Director
• John C Martin,
  Director
• Otello Stampacchia,
  Director
• Fund V, L.P.Omega Fund V Gp...,
  
• Jorge Di Martino,
  Chief Medical Officer & VP
• Backer Marianne De,
  Director
• Roshawn A. Blunt,
  
• Roger D Dansey,
  
• David M Tanen,
  
• Joshua A Kazam,
  
• Allison Frisbee,
  SR VP, CORP OPERATIONS & LEGAL
• Charles Y Lin,
  SR VP, RESEARCH & DEVELOPMENT
• Elizabeth A Olek,
  SR VP, CLINICAL SCIENCE
• Taiyin Yang,
  
• Elena Ridloff,
  
• Katherine V Stultz,
  
• Deborah Knobelman,
  Chief Financial Officer